Home

An Overview of NADDI

Established in 1989, the National Association of Drug Diversion Investigators, Inc. (NADDI) is a unique membership organization whose members are responsible for investigating and prosecuting pharmaceutical drug diversion. The organization has proven to be a valuable asset to law enforcement, the pharmaceutical industry and health regulatory personnel.

NADDI's objective is simple: to improve the members' ability to investigate, and prosecute, pharmaceutical drug diversion.

NADDI's principle activities are:

  1. Cooperative education and training in the specifics of pharmaceutical drug diversion, investigation, prosecution and prevention;
  2. Sharing investigative information and communicating with a wide variety of interested parties with regard to the nature, scope and impact of pharmaceutical drug diversion;
  3. Developing more effective measures to combat the problem.
NADDI "Seed" Grant
The National Association of Drug Diversion Investigators (NADDI) is pleased to announce a new grant available to law enforcement designated the NADDI “Seed” Grant. This grant is sponsored by Abbott Laboratories, and is designed to provide funds and expertise to law enforcement agencies across the country, with the ultimate goal of reducing prescription drug abuse.

These funds are to be used for the express purpose of law enforcement agencies initiating at least one full-time officer to devote his/her time to the issues involving prescription drug abuse. Agencies that have a part-time officer involved in drug diversion investigations will still qualify. Although the grant period is initially one year, it is the hope that this new investigative service would continue beyond the initial year.

The author of the application must be the highest ranking law enforcement officer of the agency (chief,sheriff,etc.), who must also pledge that he/she will be making this new full-time assignment for the period of at least one year, with one or more specific investigator/s.

  • The application will be a narrative, with no formal application forms provided by NADDI. The application should include in part:
  • Size and number of LE agencies involved
  • Size and population of area covered by the drug diversion investigator
  • Discussing the prescription drug problem, and its extent within the applicant’s jurisdiction
  • Overall plan for implementing the drug diversion investigations
  • Plans for promoting the new investigations through the media and other sources
  • Plans for drug diversion prevention/education offered to other LE agencies, health professionals, and the general public
  • Innovative ideas or additional plans

The grantee investigator will be provided all travel expenses to visit and review established drug diversion units. The grantee will provide the investigator with his/her usual salary and any overtime, if needed.

NADDI will provide experienced drug diversion investigators to travel to grantee’s location to assist in the advent of this investigative service. These same experienced investigators will provide ongoing assistance and mentoring to the grantee for the entire year of the grant period. The grant period will begin upon receipt of the funds from NADDI, and continue for one complete year until its completion.

The grantee agency will receive a cash award of $25,000 to be used exclusively toward the drug diversion operation, in any way deemed fit by the applicant.

The successful applicant will also provide NADDI with:
  • Quarterly reports of the progress that will include arrests, pharmaceutical statistics, prescription drugs seized, health professional investigations, and education/prevention provided to LE, health professionals, and the general public.
  • Methods of promotion of the new investigative services and an overall summary of the accomplishments and difficulties encountered during the process.
  • Quarterly reports detailing the expenditure of the funds


Applications for this grant will be accepted beginning January 1, 2008, and should be mailed to:

NADDI LE “Seed” Grants
P.O. Box 531
Manchester, Maryland 21102

There are no deadlines for grant applications, but the grant will end for the year when funds are expended.

Grant applications will be reviewed by the Executive Director and President of NADDI, who will make the final selections. Any questions on this grant should be directed to:

Charlie Cichon, Executive Director
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
443-398-6257

John Burke, President
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
513-623-3278
 

What is NADDI?

The National Association of Drug Diversion Investigators (NADDI) is a non-profit 501(c)(3) organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies, pharmaceutical manufacturers in the investigation and prevention of prescription drug abuse and diversion. NADDI also sponsors and conducts specialized educational seminars and conferences.

NADDI Federal Tax ID #52 1660752
©2006 National Association of Drug Diversion Investigators